Date:10/15/2010

n the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including t
'/>"/>

SOURCE Sanofi-aventis Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
3. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
4. Omeros Successfully Unlocks Orphan GPCRs
5. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
6. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
7. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
10. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
11. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference